Loading... Please wait...


Our Newsletter

Axitinib (AG 013736)

  • Axitinib  200x200
  • Axitinib  600x600
Catalog #:

Product Description

Axitinib (AG 013736) is a potent multi-target tyrosine kinase inhibitor (TKI), which inhibits VEGFR1, VEGFR2, VEGFR3, PDGFR?, PDGFR? and c-Kit with IC50 values of 1.2 nM, 0.2 nM, 0.1 nM-0.3 nM, 1.6 nM, 5.0 nM, and 1.7 nM, respectively. [1] In human xenograft tumor models (nude mice), Axitinib (AG 013736) shows consistent antitumor efficacy across various tumor types, which is associated with reduction in vascular angiogenesis and tumor proliferation and increase in tumor apoptosis. [1]

Axitinib (AG 013736) resulted in significantly longer progression-free survival compared with sorafenib and has been approved as a second-line therapy of advanced renal cell carcinoma. [2]

Technical information:

Chemical Formula:   C22H18N4OS
CAS #:   319460-85-0
Molecular Weight:   386.47
Purity:   > 98%
Appearance:   White
Chemical Name:   N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   Axitinib, AG 013736

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.


1. Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008; 14(22):7272-83 Pubmed ID: 19010843
2. Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors (FavorAx). clinicaltrials.gov/NCT02700568

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the Axitinib (AG 013736) to your wish list.

You Recently Viewed...